Publications

Authors: Howard Wolpert, William H Polonsky, David Rodbard Abstract The advent of connected insulin pens will generate an avalanche of digital insulin data, especially in the context of prandial- and multiple daily injection-insulin regimens. There is a need for the diabetes community to develop standards for such data, analogous to what has been achieved using the ambulatory glucose profile and

Authors: Frank J Snoek, Lawrence Fisher, William H Polonsky, Heather Stuckey, Danielle Hessler, Tricia Tang, Norbert Hermanns, Xavier Mundet, Maria Silva, Jackie Sturt, Kentaro Okazaki, Irene Hadjiyianni, Urvi Desai, Magaly Perez-Nieves Abstract Despite the demonstrated benefits of using insulin, nearly a third of the patients with type 2 diabetes (T2D) are initially reluctant to initiate insulin therapy when it is

Authors: Chioma Uzoigwe, Michael Radin, Carol M Hamersky, Mitch DeKoven, Cassie Holt, Swapna Karkare, William H Polonsky Abstract Purpose: Five quality of life (QoL) domains are particularly important to patients with type 2 diabetes (T2D) using basal insulin-sense of physical well-being, sense of safety regarding hypoglycemia, sense of diabetes as burdensome, feelings of freedom and flexibility, and sleep quality. Methods:

Authors: Arndís F Ólafsdóttir, Jan Bolinder, Tim Heise, William Polonsky, Magnus Ekelund, Magnus Wijkman, Aldina Pivodic, Elsa Ahlén, Erik Schwarcz, Thomas Nyström, Jarl Hellman, Irl B Hirsch, Marcus Lind Abstract Aim: To identify responders to continuous glucose monitoring (CGM) in relation to reductions in HbA1c and percentage of time spent in hypoglycaemia after initiation of CGM for individuals with type

Author: William H. Polonsky Abstract Editor’s Note: This article is adapted from the virtual address Dr. Polonsky delivered as the recipient of the American Diabetes Association’s (ADA’s) Outstanding Educator in Diabetes Award for 2020. He delivered the address in June 2020 during the Association’s 80th Scientific Sessions, held online as a result of the coronavirus disease 2019. Source: https://pubmed.ncbi.nlm.nih.gov/33627999/

Authors: Timothy Gilbert, Adam Noar, Olivia Blalock, William Polonsky Abstract Background: Initiating continuous glucose monitoring (CGM) can affect hemoglobin A1c (HbA1c) levels and patients’ relationship with their diabetes. We used real-world HbA1c data to quantify short-term changes in glycemia and validated psychosocial questionnaires to assess changes in quality-of-life indicators in people during their first few months of CGM use. Methods:

Authors: Marcus Lind, Arndís F Ólafsdóttir, Irl B Hirsch, Jan Bolinder, Sofia Dahlqvist, Aldina Pivodic, Jarl Hellman, Magnus Wijkman, Erik Schwarcz, Henrik Albrektsson, Tim Heise, William Polonsky Abstract Objective: Continuous glucose monitoring (CGM) reduces HbA1c and time spent in hypoglycemia in people with type 1 diabetes (T1D) treated with multiple daily insulin injections (MDI) when evaluated over shorter time periods.

Authors: W H Polonsky, A L Fortmann Abstract Aims: To investigate the impact of time in range (TIR) on mood in adults with type 1 diabetes (T1D). Methods: We followed a cohort of 219 T1D adults, all currently employing a real-time continuous glucose monitoring system (RT-CGM), to investigate how daily changes in CGM metrics were associated with nightly reports of

Authors: Lawrence Fisher, William Polonsky, Adijat Asuni, Yasmin Jolly, Danielle Hessler Abstract Aims: To describe the effects of the COVID-19 pandemic on adults with T1D or T2D in the U.S. Methods: Participants, recruited from the Taking Control of Your Diabetes Research Registry, were ≥19 years old and diagnosed with either T1D or T2D for ≥12 months. Participants completed an online

Authors: William H Polonsky, Jennifer E Layne, Christopher G Parkin, Coco M Kusiak, Nathan A Barleen, David P Miller, Howard Zisser, Ronald F Dixon Abstract The Onduo Virtual Diabetes Clinic is a telehealth program for people with type 2 diabetes that combines mobile app technology, remote personalized lifestyle coaching, connected blood glucose meters, real-time continuous glucose monitoring (rtCGM) devices, and